Onxeo announces positive DSMB recommendation for continuation of Livatag® ReLive study in HCC

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
drugs, today announced that it has received a unanimous recommendation from the
Data Safety Monitoring Board (DSMB), the independent European board of experts
that monitors the safety of the Livatag® Phase III trial, “ReLive”, to continue
the study without modification. This marks the seventh positive DSMB
recommendation and further confirms the acceptable safety profile of Livatag.

ReLive is an ongoing international, randomized Phase III trial designed to
evaluate the efficacy of Livatag® in patients with advanced hepatocellular
carcinoma (HCC) (primary liver cancer) after failure or intolerance to
sorafenib. The study, which plans to enroll a total of 400 patients, compares
intravenous administration of Livatag® to the best standard of care.

The DSMB meets regularly, twice a year, to review the safety data of the ReLive
trial and subsequently issues recommendations on the conduct of the study.

To date, more than 50% of the patients have been randomized in the study. The
DSMB has reviewed the safety data from these patients, totaling more than 500
infusions of Livatag® in the trial and for the seventh time since study
initiation, has unanimously recommended to continue the study without
modification, based on its positive assessment of the safety data of Livatag®.

“This latest positive recommendation from our independent board of experts
confirms once again Livatag®’s acceptable safety profile, based on safety data
collected on a substantial number of patients. These data certainly strengthen
our confidence in the potential of this product, which represents a potential
significant breakthrough in the treatment of hepatocellular carcinoma, a very
severe cancer with a high unmet medical need,” commented Judith Greciet, CEO of
Onxeo.

About hepatocellular carcinoma

Hepatocellular carcinoma (HCC) or hepatocarcinoma is the most common of the
primary liver cancers (85% to 90%). According to Globocan (2012 data), liver
cancer is the sixth most common cancer in terms of incidence (782,000 new cases
worldwide each year, 5.6% of all new cancer cases) with the second highest
mortality rate (746,000 deaths, 9.1% of the total) after lung cancer. The risk
factors are well known: infection by hepatitis viruses (B and C),
overconsumption of alcohol (another major cause of cirrhosis) and metabolic
diseases, especially obesity, a growing cause of cirrhosis and HCC.

About Livatag®(doxorubicin Transdrug™)

Livatag® (Doxorubicin Transdrug™) is a doxorubicin formulation in the form of
lyophilized nanoparticles of polyisohexylcyanoacrylate (PIHCA).This new
therapeutic approach allows drug resistance to be avoided by short-circuiting
the mechanisms of multi-drug resistance developed by tumor cells through the
masking of the anticancer agent. Acting as a ‘Trojan horse,’ the nanoparticle
formulation avoids rejection of doxorubicin outside the cell so that it can
exert its cytotoxic action. By specifically targeting tumor cells in the liver
and overcoming resistance to doxorubicin, Livatag® represents a significant
breakthrough in the treatment of this cancer. The first indication of this
product is hepatocellular carcinoma; the sixth most widespread cancer in the
world and the second cause of cancer-related death.

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives designed to “make the difference”. The Onxeo team is determined to
develop innovative medicines that provide patients with hope and significantly
improve their lives.

Key orphan oncology products at the advanced development stage are:

Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma

Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive
final results

Beleodaq® (belinostat): registered in the US in 2nd line treatment of peripheral
T-cell lymphoma

For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51194830&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=d31b9a2cd6308ee6d0c84b3f00d1b11f)

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51194830&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=2&md5=e1c5ce4a405871d6434af1e3350ce4f7)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51194830&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=3&md5=daad1eca84a8eecffa2c05118c6da4a1)).
Onxeo S.A.
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Alize RP
Caroline Carmagnol / Sophie Colin
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 1 44 54 36 62